Source-grounded facts extracted from SERA PROGNOSTICS, INC.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
SERA PROGNOSTICS, INC. shareholders approved Ratification of Ernst & Young LLP as Independent Registered Public Accounting Firm at the 2026-06-04 meeting.
“2. Auditor Ratification Shares Voted For Shares Voted Against Shares Abstaining Broker Non-votes 24,917,046 856,113 44 —”
SERA PROGNOSTICS, INC. shareholders approved Election of Class II Directors at the 2026-06-04 meeting.
“1. Election of Directors Nominee Shares Voted For Shares Voted to Withhold Authority Broker Non-votes Kim Kamdar, Ph.D. 9,749,623 3,062,352 12,961,228 Sandra A. J. Lawrence 12,483,966 328,009 12,961,228”
Jeffrey T. Elliott resigned as member of the Board of Directors at SERA PROGNOSTICS, INC..
“Jeffrey T. Elliott, a member of the Board of Directors (the “Board”) of Sera Prognostics, Inc. (the “Company”), notified the Company of his decision to resign from the Board effective as of June 4, 2026”
SERA PROGNOSTICS, INC. reported the first quarter ended March 31, 2026 results: revenue $14,000, net income $8.4 million.
“First quarter 2026 revenue was $14,000 compared to $38,000 for the first quarter of 2025.”
SERA PROGNOSTICS, INC. reported financial results for the fourth quarter and fiscal year ended December 31, 2025.
“On March 18, 2026, Sera Prognostics, Inc. issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2025 and providing business highlights.”
SERA PROGNOSTICS, INC. reported first quarter ended March 31, 2024 results: revenue nil, net income $8.1 million loss.
“First quarter 2024 revenue before adjustments was $39,000 compared to $100,000 for the same period of 2023, but net revenue was nil after our periodic review of accounting estimates for older tests.”
SERA PROGNOSTICS, INC. reported financial results for the fourth quarter and fiscal year ended December 31, 2023.
“On March 20, 2024, Sera Prognostics, Inc. (the "Company") issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2023 and providing business highlights.”
SERA PROGNOSTICS, INC. amended Amendment No. 2 with Baker Bros. Advisors LP and certain affiliates (effective 2023-12-06).
“On December 6, 2023, Sera Prognostics, Inc. (the “Company”) entered into the second amendment (“Amendment No. 2”) to that certain Side Letter, dated as of April 29, 2021 (the “Side Letter”), previously amended effective February 16, 2023, with Baker Bros. Advisors LP and certain affiliates of Baker Bros. Advisors LP (collectively, “Baker Bros. Investors”).”
SERA PROGNOSTICS, INC. reported the third quarter ended September 30, 2023 results: revenue $42,000, net income $7.2 million.
“Third quarter 2023 revenue of $42,000 compared to $87,000 for the same period of 2022. Total operating expenses were $8.2 million, down significantly from $11.3 million for the third quarter of 2022. Research and development expenses for the third quarter of 2023 were $3.5 million compared to $4.2 million for the third quarter of 2022 due primarily to lower clinical study costs. Selling, general and administrative expenses for the third quarter of 2023 were $4.6 million, down significantly from $7.0 million for the third quarter of 2022 due primarily to steps we took prior to year-end 2022 and more recently to streamline commercial operations, better focus our commercial strategy in response to market dynamics and align our administrative costs to match our current level of operations. Net loss for the third quarter of 2023 was $7.2 million compared to $10.7 million for the same quarter a year ago.”
SERA PROGNOSTICS, INC. reported the second quarter ended June 30, 2023 results: revenue $123,000, net income $10.5 million.
“our role as a leader in health diagnostics to improve the lives of women and babies through prenatal care.” Second Quarter 2023 Financial Results Second quarter 2023 revenue of $123,000 compared to $78,000 for the same period of 2022. Total operating expenses were $11.6 million, down from $11.8 million for the second quarter of 2022. Research and development”
Michael R. Foley resigned as Chief Medical Officer at SERA PROGNOSTICS, INC..
“On June 13, 2023, Michael R. Foley, M.D., notified Sera Prognostics, Inc. (the “ Company ”) of his intention to resign from the position of Chief Medical Officer of the Company, effective as of June 30, 2023, and has moved to a consulting role.”
SERA PROGNOSTICS, INC.: Amendment to certificate of incorporation to add a new paragraph THIRTEENTH permitting exculpation of officers for breaches of fiduciary duty of care (effective 2023-06-09).
“Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. As further described in Item 5.07 of this Current Report on Form 8-K (the “Report”), Sera Prognostics, Inc. (the “Company”) held its 2023 annual meeting of stockholders (the “Annual Meeting”) on June 8, 2023, at which the Company’s stockholders approved an amendment to the Company’s amended and restated certificate of incorporation (the “Certificate of Incorporation”) to add a new paragraph THIRTEENTH to the Certificate of Incorporation to permit exculpation of officers of the Company for breaches of the fiduciary duty of care to the extent permitted by recent amendments to the Delaware General Corporation Law (the “Amendment”). The Amendment is described in the Company’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on April 25, 2023 (the “Proxy Statement”) . The Amendment became effective upon the Company’s filing of a Certificate of Amendment to the”
SERA PROGNOSTICS, INC. shareholders approved Approval of amendment to certificate of incorporation to add officer exculpation provision at the 2023-06-08 meeting.
“3. Amendment to Certificate of Incorporation Shares Voted For Shares Voted Against Shares Abstaining Broker Non-votes 17,538,625 1,838,192 65,803 2,394,459”
SERA PROGNOSTICS, INC. shareholders approved Ratification of appointment of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-06-08 meeting.
“2. Auditor Ratification Shares Voted For Shares Voted Against Shares Abstaining Broker Non-votes 20,030,629 50 1,806,400 —”
SERA PROGNOSTICS, INC. shareholders approved Election of Class II directors at the 2023-06-08 meeting.
“On June 8, 2023, the Company held the Annual Meeting via live audio webcast on the Internet.”
Nadia Altomare resigned as Chief Commercial Officer at SERA PROGNOSTICS, INC..
“On May 24, 2023, Nadia Altomare notified the Company of her intention to resign from the position of Chief Commercial Officer of the Company, effective as of June 9, 2023, and is expected to move to a consulting role to effect a smooth commercial transition.”
Austin Aerts was appointed as Interim Chief Financial Officer at SERA PROGNOSTICS, INC..
“Concurrently with Mr. Moyes’s resignation, Austin Aerts, the Company’s current Vice President of Finance and Corporate Controller, was appointed as the interim Chief Financial Officer of the Company, effective June 7, 2023.”
Jay Moyes resigned as Chief Financial Officer at SERA PROGNOSTICS, INC..
“On May 22, 2023, Jay Moyes notified Sera Prognostics, Inc. (the “ Company ”) of his intention to resign from the position of Treasurer and Chief Financial Officer of the Company, effective as of June 7, 2023.”
Gregory C. Critchfield departed as President, Chief Executive Officer and Chairman of the Board at SERA PROGNOSTICS, INC..
“Gregory C. Critchfield, M.D., M.S. notified the Company of his intention to retire from the position of President and Chief Executive Officer of the Company and Chairman of the Board of Directors, effective as of June 8, 2023”
Kim Kamdar was appointed as Chairperson of the Board at SERA PROGNOSTICS, INC..
“Kim Kamdar, Ph.D., a member of the Board, has been appointed as Chairperson of the Board, effective as of the Retirement Date.”
Zhenya Lindgardt was appointed as Interim Chief Executive Officer at SERA PROGNOSTICS, INC..
“Concurrently with Dr. Critchfield’s retirement, Zhenya Lindgardt, a member of the Board, was appointed as the Interim Chief Executive Officer of the Company, effective June 8, 2023.”
Gregory C. Critchfield departed as President and Chief Executive Officer at SERA PROGNOSTICS, INC..
“On May 14, 2023, Gregory C. Critchfield, M.D., M. S. notified Sera Prognostics, Inc. (the “ Company ”) of his intention to retire from the position of President and Chief Executive Officer of the Company and Chairman of the Board of Directors (the “ Board ”), effective as of June 8, 2023.”
SERA PROGNOSTICS, INC. reported the first quarter of 2023 ended March 31, 2023 results: revenue $100,000, net income $10.6 million loss.
“should serve as an additional catalyst to help us expand the use of our PreTRM Test and to increase revenue.” First Quarter 2023 Financial Results First quarter 2023 revenue of $100,000 compared to $38,000 for the same period of 2022. Total operating expenses were $11.4 million, down from $12.3 million for the first quarter of 2022. Research and development”
SERA PROGNOSTICS, INC. reported the fiscal year ended December 31, 2022 results: revenue $268,000.
“Total full year 2022 revenue of $268,000 compared to $82,000 for full year 2021.”
SERA PROGNOSTICS, INC. reported the fourth quarter ended December 31, 2022 results: revenue $65,000, net income $9.7 million.
“Fourth quarter 2022 revenue of $65,000 compared to $26,000 for the same period of 2021. Total operating expenses were $10.5 million, down from $12.6 million for the fourth quarter of 2021. Research and development expenses for the fourth quarter of 2022 were $3.5 million compared to $3.1 million for the fourth quarter of 2021 due primarily to increased headcount and research activities. Selling, general and administrative expenses for the fourth quarter of 2022 were $6.9 million, down significantly from $9.5 million for the year-ago period due primarily to steps we took during the prior quarter to streamline our sales operations and to better focus our commercial strategy in response to market dynamics, as well as decreased administrative costs resulting from operational efficiencies. Net loss for the fourth quarter of 2022 was $9.7 million compared to $12.5 million for the same quarter a year ago.”
SERA PROGNOSTICS, INC. reported the third quarter ended September 30, 2022 results: revenue $87,000, net income $10.7 million.
“traction that we believe will create a more significant impact on our top-line results in 2023 and beyond.” Third Quarter 2022 Financial Results Third quarter 2022 revenue of $87,000 compared to $23,000 for the same period of 2021. Total operating expenses were $11.3 million, up from $9.5 million for the third quarter of 2021. Research and development expenses”
Jane F. Barlow was appointed as Class I Director at SERA PROGNOSTICS, INC..
“On April 11, 2022, the Board of Directors (the “Board”) of Sera Prognostics, Inc. (the “Company”) appointed Jane F. Barlow, M.D., MPH, MBA, effective April 11, 2022 (the “Effective Date”), as a director to the Board to serve as a Class I Director with a term expiring at the Company’s 2022 annual meeting of stockholders.”
Sandra A.J. Lawrence was appointed as Director at SERA PROGNOSTICS, INC..
“On November 29, 2021, the Board of Directors (the “Board”) of Sera Prognostics, Inc. (the “Company”) appointed Sandra A.J. Lawrence, effective November 29, 2021 (the “Effective Date”), as a director to the Board to serve as a Class II Director with a term expiring at the Company’s 2023 annual meeting of stockholders.”
Evguenia (Zhenya) Lindgardt was appointed as Director at SERA PROGNOSTICS, INC..
“On November 8, 2021, the Board of Directors (the “Board”) of Sera Prognostics, Inc. (the “Company”) appointed Evguenia (Zhenya) Lindgardt, effective November 8, 2021 (the “Effective Date”), as a director to the Board to serve as a Class III Director with a term expiring at the Company’s 2024 annual meeting of stockholders.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.